Cell Culture Dish blog, we interviewed Dr. Jimmy Li, CEO of WuXi XDC, a WuXi Biologics subsidiary. To read or hear the first podcast go here. We discussed the reasons for the formation of WuXi XDC, which was established via a joint venture between WuXi Biologics and WuXi STA, a WuXi AppTec subsidiary, and how a one-stop Contract Research, Development and Manufacturing Organization (CRDMO) greatly streamlines the pathway to the clinic for companies developing antibody drug conjugates (ADCs). He also shares new technologies available to make the development of Antibody Drug Conjugates (ADCs) more efficient and effective.

">
Telephone sharing button Contact Us linkedin sharing button Linked In wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Locations

Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 580,000 liters by 2026.

United States
Massachusetts
U.S.
189,500sq. ft.
Operational2024
New Jersey
U.S.
66,000sq. ft.
Operational2021
Pennsylvania
U.S.
33,000sq. ft.
OperationalOctober. 2020
Ireland
Dundalk
Ireland
26Hectare campus
Operational2022
WuXi Vaccines
Ireland
$240Million investment
Operational2022
Germany
Leverkusen
Germany
13,000+sq.m. facility
Operations2020
Wuppertal
Germany
30,000+sq.m.
Operations2021
Singapore
Singapore
$1.4Billion investment
OverTen Years
China
Shanghai
Waigaoqiao Free Trade Zone
200,000 sq.ft
Opened April 2018
Shanghai
Fengxian District
1.6 millionsq. ft.
Planned2021
Wuxi
15,296sq.m.
OpenedOctober 2012
Suzhou
16,000sq. m.
OpenedDecember 2014
Hangzhou
30,000sq. m.
Operations2021
Chengdu
314,000sq. m.
Planned2023
Shijiazhuang
82,160sq. m.
Planned2022
Hangzhou
50,000sq. m.
Operations2021
Suzhou
11,500sq. m.
Operations2021